EUVIMEDEUVIMED entdecken
Crossref

Predictive Factors for Long-Term High Responders to Upadacitinib Treatment in Patients with Atopic Dermatitis

Teppei Hagino iD, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Dermatitis® · 2025

DOI: 10.1089/derm.2024.0230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatitis®, 2025. Verfasst von Teppei Hagino und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Upadacitinib, a Janus kinase 1 inhibitor, is an effective medicine for moderate-to-severe atopic dermatitis (AD). Identifying long-term responders to upadacitinib is crucial for optimal treatment strategies in real-world clinical practice. To identify predictive factors for long-term high responders to upadacitinib 15 mg or 30 mg, defined as achievers of investigator’s global assessment (IGA) 0/1 with ≥2-point improvement from baseline IGA at week 48.

Methods

A retrospective study was conducted from August 2021 to September 2023 on 63 AD patients treated with upadacitinib 15 mg and 31 patients with 30 mg. Patients of each group were categorized into long-term high responders (achievers of IGA 0/1 at week 48) and low responders (non-achievers). We compared baseline values of clinical indexes and laboratory parameters between long-term responders and nonresponders.

Results

In 15 mg group, long-term high responders showed lower rate of bronchial asthma (BA), lower values of baseline eczema area and severity index (EASI) of head and neck, IgE, and systemic inflammatory response index (SIRI) compared with low responders. In 30 mg group, long-term high responders showed lower baseline levels of IgE compared with low responders.

Conclusion

Patients with lower baseline EASI of head and neck, IgE, or SIRI or without BA and those with lower baseline IgE may have a higher potential to become long-term high responders to upadacitinib 15 mg and 30 mg treatment, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHeterocyclic Compounds, 3-RingHumansFemaleMaleRetrospective StudiesAdultSeverity of Illness IndexMiddle AgedTreatment OutcomeJanus Kinase InhibitorsYoung AdultAdolescent

Stichwörter der Autor:innen

EASI of head and neckIgESIRIatopic dermatitisbronchial asthmapredictive factorresponderupadacitinib

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingJanus Kinase Inhibitors

Autor:innen und Institutionen

  • From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino

Zitieren

APA

Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2025). Predictive Factors for Long-Term High Responders to Upadacitinib Treatment in Patients with Atopic Dermatitis. Dermatitis®. https://doi.org/10.1089/derm.2024.0230

Vancouver

Hagino T, Saeki H, Fujimoto E, Kanda N. Predictive Factors for Long-Term High Responders to Upadacitinib Treatment in Patients with Atopic Dermatitis. Dermatitis®. 2025. doi:10.1089/derm.2024.0230

BibTeX
@article{Hagino2025,
  author = {Hagino, Teppei and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
  title = {Predictive Factors for Long-Term High Responders to Upadacitinib Treatment in Patients with Atopic Dermatitis},
  journal = {Dermatitis®},
  year = {2025},
  doi = {10.1089/derm.2024.0230}
}
Kostenlos starten →